New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
12:38 EDTMYGN, MRK, BIRT, CVS, SSYS, USNA, GOOG, DDDOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday after ADP reported that dismal weather in January put a damper on private sector hiring. The market seemed indecisive in the opening 30 minutes of trading, but soon picked up downside momentum. The Nasdaq, which was down more than 1% early in the session, has trimmed its losses and the Dow has moved into positive ground, though just barely. ECONOMIC EVENTS: In the U.S., payroll company ADP reported that 175,000 service jobs were created in January, versus the expectations for 185,000 net new positions to have been added. The ISM services index rose to 54.0 in January from December's 53.0 reading, which was a bit ahead of expectations. COMPANY NEWS: Dow component Merck (MRK) advanced fractionally after the drug company’s quarterly results were generally in-line with expectations and it also announced three clinical collaboration agreements to evaluate its investigational anti-PD-1 immunotherapy… Shares of Google (GOOG) are advancing in a down market after the search giant reached a settlement with European Union regulators over antitrust allegations and research firm Bernstein hiked its price target on the stock to $1,500 from $1,350... CVS Caremark (CVS) announced plans to cease selling all tobacco products, including cigarettes, at all its locations starting October 1. MAJOR MOVERS: Among the notable gainers was multi-level-marketer USANA Health Sciences (USNA), which rose 17% after its results and guidance beat expectations. Also higher were shares of molecular diagnostic company Myriad Genetics (MYGN), which climbed over 11% after the company reported second quarter results that beat consensus expectations, raised its fiscal 2014 outlook, and announced the acquisition of Crescendo Bioscience. Among the noteworthy losers was 3D Systems (DDD), which plunged 16% after the maker of 3D printers and supplies lowered its profit outlook for the current fiscal year and guided to earnings next year below the consensus estimate. A number of 3D Systems’ peers fell as well, with the next biggest company in the sector, Stratasys (SSYS), also declining 3%. Also lower were shares of Actuate (BIRT), which slid about 17% after reporting earnings, announcing the acquisition of German software developer legodo ag and being downgraded at Drexel Hamilton. INDICES: Near midday, the Dow was up 13.12, or 0.08%, to 15,458.36; the Nasdaq was down 13.59, or 0.34%, to 4,017.93; and the S&P 500 was down 2.14, or 0.12%, to 1,753.06.
News For DDD;SSYS;MRK;GOOG;CVS;MYGN;USNA;BIRT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 19, 2014
08:02 EDTGOOGApple's top competition is Google, says Jefferies
Jefferies calls Google (GOOG) Apple's (AAPL) top competition after its analysis indicated that the search engine giant provides the majority of most popular Consumer Cloud Services, which it believes are expanding penetration through Android, Chrome, iOS, Windows and other devices. By contrast, Apple's iCloud remains focused on iOS devices, Jefferies points out. It keeps a Hold rating on Apple shares, saying Google dominates as provider of the most popular services, including Search, Maps, Chrome, and YouTube. To reflect positive supply chain data points, Jefferies raised its FY15 earnings estimate for Apple to $8.52 to $8.01. It also upped its price target for Apple shares to $120 from $112. The stock closed yesterday up $1.48 to $115.47.
07:52 EDTMRKInforma Business Information to hold a conference
Subscribe for More Information
07:08 EDTMYGNCrescendo data shows Vectra DA is better predictor of joint damage in RA
Subscribe for More Information
November 18, 2014
09:27 EDTGOOGGoogle's Q4 gross ad revenues tracking slightly ahead, says ITG Research
ITG Research said Google's Q4 gross ad revenue is tracking to $16.35B vs. consensus of $16.29B.
06:39 EDTMRKAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
06:08 EDTGOOGIntel's 'Mica' bracelet to feature Google alerts, AT&T data plan, Re/code says
Subscribe for More Information
November 17, 2014
13:12 EDTSSYS, DDD3D Systems rises after insider buy, Voxeljet slips after downgrade
Subscribe for More Information
11:55 EDTMRKMerck says IMPROVE-IT study met all primary, secondary endpoints
Merck announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN – which combines simvastatin with the non-statin ZETIA -- experienced significantly fewer major cardiovascular events than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions. Merck plans to submit the data from IMPROVE-IT to the U.S. Food and Drug Administration in mid-2015 to support a new indication for reduction of major cardiovascular events for VYTORIN and ZETIA. VYTORIN and ZETIA are currently indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia. The current U.S. Prescribing Information for both products states that the effect of ezetimibe on cardiovascular morbidity and mortality, alone or incremental to statin therapy, has not been determined.
10:38 EDTSSYSStratasys announces partnership with Martha Stewart Living Omnimedia
Subscribe for More Information
09:57 EDTDDD3D Systems up 3.5% in early trading following Chairman stock purchase
Subscribe for More Information
08:34 EDTMRKMerck says IMPROVE-IT met primary endpoint
Subscribe for More Information
06:23 EDTGOOGFacebook working on 'Facebook at Work' website, FT reports
Subscribe for More Information
06:10 EDTGOOGGoogle partners with Telstra to test Project Loon in Australia, SMH reports
Subscribe for More Information
November 16, 2014
13:26 EDTMRKMerck: KEYTRUDA showed superiority to chemotherapy for primary endpoint of PFS
Subscribe for More Information
November 14, 2014
17:07 EDTGOOGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
14:53 EDTMRK, CVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:46 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
10:10 EDTDDDOptions with decreasing implied volatility
Subscribe for More Information
07:14 EDTMYGNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:00 EDTGOOGGoogle to retire Google Wallet for digital goods API on March 2, 2015
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use